JP2013500739A - 新規タンパク質 - Google Patents

新規タンパク質 Download PDF

Info

Publication number
JP2013500739A
JP2013500739A JP2012523432A JP2012523432A JP2013500739A JP 2013500739 A JP2013500739 A JP 2013500739A JP 2012523432 A JP2012523432 A JP 2012523432A JP 2012523432 A JP2012523432 A JP 2012523432A JP 2013500739 A JP2013500739 A JP 2013500739A
Authority
JP
Japan
Prior art keywords
polypeptide
antibody
disease
cancer
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500739A5 (enExample
Inventor
サンドラー、タマラ
デバリー、オルリー
Original Assignee
ツー トゥー バイオテック リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツー トゥー バイオテック リミテッド filed Critical ツー トゥー バイオテック リミテッド
Publication of JP2013500739A publication Critical patent/JP2013500739A/ja
Publication of JP2013500739A5 publication Critical patent/JP2013500739A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
JP2012523432A 2009-08-02 2010-08-02 新規タンパク質 Pending JP2013500739A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL200202A IL200202A0 (en) 2009-08-02 2009-08-02 Novel proteins
IL200202 2009-08-02
PCT/IL2010/000621 WO2011016026A2 (en) 2009-08-02 2010-08-02 Novel proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015047903A Division JP5833780B2 (ja) 2009-08-02 2015-03-11 新規タンパク質
JP2015155720A Division JP2015212302A (ja) 2009-08-02 2015-08-06 新規タンパク質

Publications (2)

Publication Number Publication Date
JP2013500739A true JP2013500739A (ja) 2013-01-10
JP2013500739A5 JP2013500739A5 (enExample) 2013-09-12

Family

ID=42263570

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012523432A Pending JP2013500739A (ja) 2009-08-02 2010-08-02 新規タンパク質
JP2015047903A Expired - Fee Related JP5833780B2 (ja) 2009-08-02 2015-03-11 新規タンパク質
JP2015155720A Pending JP2015212302A (ja) 2009-08-02 2015-08-06 新規タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015047903A Expired - Fee Related JP5833780B2 (ja) 2009-08-02 2015-03-11 新規タンパク質
JP2015155720A Pending JP2015212302A (ja) 2009-08-02 2015-08-06 新規タンパク質

Country Status (11)

Country Link
US (1) US8647632B2 (enExample)
EP (2) EP2461829B1 (enExample)
JP (3) JP2013500739A (enExample)
KR (1) KR101623355B1 (enExample)
CN (1) CN102596247B (enExample)
AU (1) AU2010280368B2 (enExample)
CA (1) CA2769001C (enExample)
IL (3) IL200202A0 (enExample)
IN (1) IN2012DN00879A (enExample)
SG (2) SG178097A1 (enExample)
WO (1) WO2011016026A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766983B2 (en) 2015-03-05 2020-09-08 Sekisui Specialty Chemicals America, Llc PVOH dispersant for VCM polymerization

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742061A4 (en) * 2011-08-08 2015-05-27 Two To Biotech Ltd NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND USES THEREOF IN METHODS FOR THE TREATMENT OF METABOLIC, CARDIAC AND IMMUNE DISORDERS
CN105916874A (zh) * 2014-01-02 2016-08-31 两合生物科技有限公司 新型多肽
CN104262468B (zh) * 2014-09-28 2017-01-18 新乡医学院 一种葡萄糖转运蛋白抑制多肽及其制备方法、应用
KR102713301B1 (ko) 2015-12-11 2024-10-02 고쿠리츠다이가쿠호진 고치다이가쿠 췌장암 및 췌장관 내 유두상 점액성 종양의 마커

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5286846A (en) 1991-06-14 1994-02-15 The Government Of The United States Of America As Represented By The Dept. Of Health And Human Services Amino acid derivative and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
AU2001261513A1 (en) * 2000-05-15 2001-11-26 Braswell, Glenn A. Composition and method for increasing testosterone levels
US6566333B2 (en) 2000-06-19 2003-05-20 Uab Research Foundation Osteoclast secreted chemokine and uses thereof
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
WO2006042002A2 (en) 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US20080248134A1 (en) 2005-05-04 2008-10-09 Auckland Uniservices Limited Oral compositions, use and combinations of N-[2-(dimethylamino)ethyl]-2,6 dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide and closely related analogues thereof
EP2097538A4 (en) * 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6014047834; Ｄｉａｂｅｔｅｓ Ｖｏｌ．４６，　Ｎｏ．１, 1997, ｐｐ．１１-１６ *
JPN6014047835; Ｂｉｏｃｈｅｍ．　Ｊ． Ｖｏｌ．３５７，　Ｐｔ．１, 2001, ｐｐ．１２７-１３５ *
JPN6014047837; Ｄｉａｂｅｔｏｌｏｇｉａ Ｖｏｌ．４８，　Ｎｏ．１, 2005, ｐｐ．１３２-１３９ *
JPN6014047839; Ｏｂｅｓ．　Ｒｅｖ． Ｖｏｌ．６，　Ｎｏ．１, 2005, ｐｐ．１３-２１ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766983B2 (en) 2015-03-05 2020-09-08 Sekisui Specialty Chemicals America, Llc PVOH dispersant for VCM polymerization

Also Published As

Publication number Publication date
AU2010280368A1 (en) 2012-03-15
AU2010280368B2 (en) 2015-07-23
IL240134A0 (en) 2015-09-24
EP2461829B1 (en) 2016-01-06
EP2985035A1 (en) 2016-02-17
HK1171672A1 (zh) 2013-04-05
CN102596247A (zh) 2012-07-18
IN2012DN00879A (enExample) 2015-07-10
SG10201404735VA (en) 2014-10-30
US20120121602A1 (en) 2012-05-17
IL200202A0 (en) 2010-05-31
JP5833780B2 (ja) 2015-12-16
IL217758A0 (en) 2012-03-29
CA2769001A1 (en) 2011-02-10
CN102596247B (zh) 2014-08-06
WO2011016026A3 (en) 2011-05-26
EP2461829A2 (en) 2012-06-13
KR20120063474A (ko) 2012-06-15
IL217758A (en) 2015-10-29
KR101623355B1 (ko) 2016-05-23
SG178097A1 (en) 2012-03-29
EP2461829A4 (en) 2013-06-19
CA2769001C (en) 2016-07-26
US8647632B2 (en) 2014-02-11
WO2011016026A2 (en) 2011-02-10
JP2015212302A (ja) 2015-11-26
IL240134A (en) 2016-07-31
JP2015157811A (ja) 2015-09-03

Similar Documents

Publication Publication Date Title
JP6502851B2 (ja) 炎症性状態の予防、処置、および診断のための方法および化合物
JP5833780B2 (ja) 新規タンパク質
CN110944666B (zh) 杂交瘤克隆、vsig-4的单克隆抗体，以及制备和使用的方法
CN105622757A (zh) 结合赖氨酰氧化酶样2（loxl2）的抗体和其使用方法
US7034118B2 (en) Corticotropin-releasing factor2 receptors
US9150642B2 (en) Anti-KTPAF50 antibodies and their uses in therapeutic and diagnostic methods
CN105026422A (zh) Sh2结构域变体
US20250216395A1 (en) Compositions and methods comprising anti-nrp2 antibodies
CA2624562A1 (en) Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
US9296786B2 (en) Shortened secreted polypeptides
JP7849292B2 (ja) 潜伏形態のトキソプラズマ症についての新たな血清マーカー
JP5354634B2 (ja) ヒトａｂｈ８タンパク質、それをコードする遺伝子、およびこれらの治療的又は診断的用途
AU2003227862B2 (en) An EPHRIN-B receptor protein involved in carcinoma
US7667013B2 (en) Gene encoding a guanine nucleotide exchange factor and the gene product thereof
HK1171672B (en) Novel proteins
JP2001508297A (ja) ヒトエンドスルフィン遺伝子
JP2004166695A (ja) ＲＡＰＬ・Ｒａｐ１相互作用制御

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150430